Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Startet die Aktie jetzt durch: XPeng: Elektroautos, Humanoide Roboter und Robotaxi - Chinesen geben Gas (Wallstreet-Online) +++ XPENG ADR Aktie +3,13%

ESPERION Aktie

 >ESPERION Aktienkurs 
2.528 EUR    -1.5%    (TradegateBSX)
Ask: 2.506 EUR / 3990 Stück
Bid: 2.449 EUR / 4090 Stück
Tagesumsatz: 5148 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
ESPERION Aktie über LYNX handeln
>ESPERION Performance
1 Woche: -12,1%
1 Monat: -9,8%
3 Monate: -24,2%
6 Monate: +13,0%
1 Jahr: +70,6%
laufendes Jahr: -25,2%
>ESPERION Aktie
Name:  ESPERION THERAPEUTICS
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US29664W1053 / A1W1SJ
Symbol/ Ticker:  0ET (Frankfurt) / ESPR (NASDAQ)
Kürzel:  FRA:0ET, ETR:0ET, 0ET:GR, NASDAQ:ESPR
Index:  -
Webseite:  https://www.esperion.com/
Profil:  Esperion Therapeutics Inc. is a biopharmaceutical company committed to developing and commercializing innovative lipid-lowering therapies to address cardiovascular disease. Its primary focus is on cre..
>Volltext..
Marktkapitalisierung:  559.68 Mio. EUR
Unternehmenswert:  992.7 Mio. EUR
Umsatz:  261.49 Mio. EUR
EBITDA:  -25.22 Mio. EUR
Nettogewinn:  -91.09 Mio. EUR
Gewinn je Aktie:  -0.46 EUR
Schulden:  517.27 Mio. EUR
Liquide Mittel:  79.57 Mio. EUR
Operativer Cashflow:  -80.29 Mio. EUR
Bargeldquote:  0.26
Umsatzwachstum:  -2.43%
Gewinnwachstum:  -15.73%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  ESPERION
Letzte Datenerhebung:  10.03.26
>ESPERION Kennzahlen
Aktien/ Unternehmen:
Aktien: 239.06 Mio. St.
Frei handelbar: 95.97%
Rückkaufquote: -0.92%
Mitarbeiter: 304
Umsatz/Mitarb.: 0.94 Mio. EUR
Analysten:
Analystenrating: Buy
Kursziel: 154.37%
Bewertung:
KGV: -
KGV lG: -
KUV: 2.03
KBV: -
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: 58.2%
Gewinnmarge: -34.84%
Operative Marge: -9.67%
Managementeffizenz:
Gesamtkaprendite: -31.21%
Eigenkaprendite: -
>ESPERION Peer Group
Gesundheit
 
10.03.26 - 14:01
Aus dem Earnings Call: Esperion Therapeutics meldet für Q4 2025 starken Umsatzanstieg, verfehlt aber Gewinnprognose (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
10.03.26 - 13:30
Esperion Therapeutics (ESPR) Misses Q4 Earnings Estimates (Zacks)
 
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -5.38% and +4.90%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?...
10.03.26 - 11:15
Esperion Therapeutics GAAP EPS of $0.22 misses by $0.05, revenue of $168.45M beats by $2.33M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
10.03.26 - 11:03
Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire EN)
 
– FY25 Total Revenue Grew 21% Y/Y to $403.1 Million; FY25 U.S. Net Product Revenue Grew 38% Y/Y to $159.6 Million –...
09.03.26 - 15:33
Esperion Therapeutics Q4 2025 Earnings Preview (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
04.03.26 - 18:15
ESPR to Boost Cardiovascular Portfolio With Corstasis Buyout for $75M (Zacks)
 
Esperion to buy Corstasis for $75M in cash, adding FDA-approved Enbumyst nasal spray to its cardiovascular franchise. The deal is likely to be closed in Q2....
04.03.26 - 12:01
Esperion to acquire Corstasis for cardiovascular franchise expansion (PBR)
 
Enbumyst is approved by the US Food and Drug Administration (FDA) for treating oedema linked to congestive heart failure, hepatic, and renal diseases in adults. The agreement will The post Esperion to acquire Corstasis for cardiovascular franchise expansion appeared first on Pharmaceutical Business review....
03.03.26 - 14:39
Esperion Acquires Enbumyst Maker Corstasis (Benzinga)
 
Esperion (ESPR) shares dip premarket after announcing a $75M deal to buy Corstasis Therapeutics, adding FDA-approved nasal spray Enbumyst. Importance Rank:  1 read more...
03.03.26 - 12:39
Esperion to acquire Corstasis for $75M upfront payment (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
03.03.26 - 12:06
Esperion Therapeutics and Corstasis Therapeutics Announce Esperion′s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) (GlobeNewswire EN)
 
– Enbumyst™ Is the First and Only FDA-Approved Nasal Spray Loop Diuretic for Edema Associated with Congestive Heart Failure, Expected to Leverage Esperion's Established Cardiovascular Commercial Infrastructure, Synergistically Expand Product Portfolio and Accelerate Double-Digit Revenue Growth –...
24.02.26 - 17:30
Esperion Therapeutics (ESPR) Earnings Expected to Grow: Should You Buy? (Zacks)
 
Esperion Therapeutics (ESPR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....
18.02.26 - 14:03
Esperion to Participate in The 2026 Citizens Life Sciences Conference (GlobeNewswire EN)
 
ANN ARBOR, Mich., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 2026 Citizens Life Sciences Conference on March 11, 2026, at 8:25 a.m. ET....
17.02.26 - 14:03
Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040 (GlobeNewswire EN)
 
ANN ARBOR, Mich., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Alkem Laboratories Ltd. (Alkem). This agreement resolves the patent litigation brought by Esperion against Alkem in response to Alkem's Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions of NEXLETOL and NEXLIZET prior to the expiration of the applicable patents. Pursuant to the agreement, Alkem has agreed not to market a generic version of either NEXLETOL or NEXLIZET in the United States prior to April 19, 2040, unless certain limited circumstances customarily included in these types of agreements occur....
11.02.26 - 22:33
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire EN)
 
ANN ARBOR, Mich., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on February 10, 2026, the Company granted 11 new employees 40,200 restricted stock units (RSUs) under Esperion's 2017 Inducement Equity Incentive Plan....
22.01.26 - 02:01
Insiderhandel: General Counsel verkauft Aktien von Esperion Therapeutics im Wert von 4868 USD (Insiderkauf)
 
Looker, Benjamin - Vorstand - Tag der Transaktion: 2026-01-20...
12.01.26 - 00:03
Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire EN)
 
– Reports $156 to $160 Million in Preliminary* Full-Year 2025 U.S. Net Product Sales, a 35% to 38% Increase Compared With Full-Year 2024 –...
05.01.26 - 14:03
Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire EN)
 
ANN ARBOR, Mich., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will present at J.P. Morgan's 44th Annual Healthcare Conference on Wednesday, January 14, 2025....
19.12.25 - 14:03
Esperion′s Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes (GlobeNewswire EN)
 
– Bempedoic Acid Highlighted by ACC for LDL-C Lowering in Patients with Peripheral Artery Disease and Diabetes Based on Proven Cardiovascular and Limb Benefits –...
19.12.25 - 01:01
Insiderhandel: Chief Financial Officer verkauft Aktien von Esperion Therapeutics im Wert von 26905 USD (Insiderkauf)
 
Halladay, Benjamin - Vorstand - Tag der Transaktion: 2025-12-17...
19.12.25 - 01:01
Insiderhandel: General Counsel verkauft Aktien von Esperion Therapeutics im Wert von 23898 USD (Insiderkauf)
 
Looker, Benjamin - Vorstand - Tag der Transaktion: 2025-12-17...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Gemeinsame Beschäftigungen und Liebhabereien sind das Erste, worin sich eine wechselseitige Übereinstimmung hervortut. - Johann Wolfgang von Goethe
>Aktien | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!